SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Medical - Drugs >

NanoString Technologies Inc (NSTG)

NSTG RSS Feed
Add NSTG Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 6/9/2017 4:10:28 PM - Followers: 1 - Board type: Free - Posts Today: 0

NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Prosigna(TM) Breast Cancer Prognostic Gene Signature Assay. Based on the PAM50 gene signature, Prosigna is the company's first FDA-cleared in vitro diagnostic assay and uses the gene expression profile of cells found in breast cancer tissue to assess a patient's risk of distant recurrence of disease. The Prosigna Assay is performed using the nCounter(R) Dx Analysis System, which can be placed in qualified laboratories throughout the United States, empowering oncologists and pathologists to quickly and easily meet the testing needs of their breast cancer patients. "Receipt of FDA 510(k) clearance for Prosigna marks a key milestone for NanoString and is an important step forward in the treatment of breast cancer. This achievement is a testament to the ongoing dedication and professionalism of our team, and the commitment of our collaborators," said Brad Gray, President and Chief Executive Officer of NanoString Technologies. "Prosigna illustrates our approach of using nCounter technology to translate genomic discoveries into powerful in vitro diagnostic products, and it represents a significant growth opportunity beyond our robust life sciences research business." The Prosigna Assay is intended for use as a prognostic indicator for distant recurrence-free survival at 10 years, and is indicated for postmenopausal women with Stage I/II lymph node-negative or Stage II lymph node-positive (one to three positive nodes) hormone receptor-positive breast cancer who have undergone surgery in conjunction with locoregional treatment consistent with standard of care. For each patient, the Prosigna Assay reports the Prosigna Score (referred to as Risk of Recurrence Score, or ROR Score, in the scientific literature, including the TransATAC study recently published in the Journal of Clinical Oncology(1)) and a risk category based on both the Prosigna Score and nodal status. Node-negative patients are classified as low, intermediate or high risk, while node-positive patients are classified as low or high risk.
SureTrader
Interactive Brokers Advertisement
NSTG
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
NSTG News: NanoString Technologies Highlights Advances in Precision Oncology at the 59th Annual Meeting of the American Society of Hemat... 12/07/2017 04:00:00 PM
NSTG News: Confidential Treatment Order (ct Order) 12/06/2017 03:57:03 PM
NSTG News: Statement of Changes in Beneficial Ownership (4) 11/15/2017 05:10:22 PM
NSTG News: Statement of Changes in Beneficial Ownership (4) 11/15/2017 05:09:57 PM
NSTG News: NanoString Highlights Record Number of nCounter-Based Research Abstracts at the 2017 Annual Meeting of the Society of Immunot... 11/09/2017 06:00:00 AM
PostSubject
#24   LEVIN CAPITAL STRATEGIES, L.P. has filed a new wiltonio 06/09/17 04:10:28 PM
#23   $NSTG recent news/filings stocktrademan 05/17/15 12:48:31 PM
#22   $NSTG DD Notes ~ http://www.ddnotesmaker.com/NSTG stocktrademan 11/24/14 01:46:51 PM
#21   Fpo good or bad? RWIII 01/14/14 10:56:10 AM
#20   Good PR release will maybe help today. zelskid 11/12/13 09:32:39 AM
#19   Numbers looked generally very good. Stock was fredugsi 11/06/13 12:17:46 PM
#18   Not much effect from quarterly report zelskid 11/06/13 10:56:58 AM
#17   End of month type of adjustments? I'm fredugsi 10/31/13 11:35:19 AM
#16   Did you see that 9% dip that recovered zelskid 10/31/13 09:51:12 AM
#15   Looks like no volume till the 3rd qtr zelskid 10/30/13 10:40:01 AM
#14   I'm in! Bought GNMK at $4 awhile fredugsi 10/22/13 05:06:26 PM
#13   Volume smaller then ever? zelskid 10/22/13 10:59:04 AM
#12   NanoString Technologies to Release Third Quarter 2013 Financial zelskid 10/16/13 05:00:49 PM
#11   Down 2.4% on low volume. zelskid 10/15/13 04:06:58 PM
#10   Channeling on low volume. zelskid 10/15/13 10:53:41 AM
#9   NanoString Technologies, Inc. and Fluidigm Corporation Settle Lawsuits zelskid 10/01/13 07:17:24 PM
#8   Closed up 4.5% zelskid 09/26/13 07:17:12 PM
#7   Finished up 4.5 % zelskid 09/26/13 04:02:07 PM
#6   Up over 5% zelskid 09/26/13 02:41:54 PM
#5   Pulling back, but still up 4% zelskid 09/26/13 10:05:41 AM
#4   What a day,up 6.8%!!!!!!!!!!!!! zelskid 09/23/13 04:12:20 PM
#3   26,200 shares just traded at $10.755 at 10:18 am zelskid 09/23/13 10:52:18 AM
#2   Please consider investing in this company. Tremendous potential.Approved zelskid 09/20/13 02:56:50 PM
#1   Thank you Investor Hub for letting me set zelskid 09/12/13 10:05:59 AM
PostSubject